Discounted Cash Flow (DCF) Analysis Levered

Syndax Pharmaceuticals, Inc. (SNDX)

$22.94

+0.13 (+0.57%)
All numbers are in Millions, Currency in USD
Stock DCF: -157,727,628,100.77 | 22.94 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.111.521.521.52139.716,483.56300,886.5813,963,427.46648,009,315.9430,072,564,537.25
Revenue (%)
Operating Cash Flow -47.37-68.53-50.61-71.2629.13-191,623.40-8,892,784.31-412,692,878.57-19,152,090,748.78-888,802,785,541.63
Operating Cash Flow (%)
Capital Expenditure -0.08-0.19-0.12-0.12-11.39-528.79-24,539.98-1,138,841.78-52,850,927-2,452,685,283.84
Capital Expenditure (%)
Free Cash Flow -47.46-68.72-50.74-71.3817.74-192,152.19-8,917,324.28-413,831,720.36-19,204,941,675.78-891,255,470,825.46

Weighted Average Cost Of Capital

Share price $ 22.94
Beta 1.243
Diluted Shares Outstanding 51.96
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.562
Total Debt -
Total Equity 1,192.02
Total Capital 1,192.02
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.111.521.521.52139.716,483.56300,886.5813,963,427.46648,009,315.9430,072,564,537.25
Operating Cash Flow -47.37-68.53-50.61-71.2629.13-191,623.40-8,892,784.31-412,692,878.57-19,152,090,748.78-888,802,785,541.63
Capital Expenditure -0.08-0.19-0.12-0.12-11.39-528.79-24,539.98-1,138,841.78-52,850,927-2,452,685,283.84
Free Cash Flow -47.46-68.72-50.74-71.3817.74-192,152.19-8,917,324.28-413,831,720.36-19,204,941,675.78-891,255,470,825.46
WACC
PV LFCF -175,385.35-7,429,002.65-314,678,959.65-13,329,224,976.96-564,601,582,141.24
SUM PV LFCF -578,253,090,465.86

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.56
Free cash flow (t + 1) -909,080,580,241.97
Terminal Value -12,024,875,400,026.10
Present Value of Terminal Value -7,617,640,393,969.12

Intrinsic Value

Enterprise Value -8,195,893,484,434.97
Net Debt -221.97
Equity Value -8,195,893,484,213.01
Shares Outstanding 51.96
Equity Value Per Share -157,727,628,100.77